TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04056897

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-132, 125 mg
Description: IV infusion every 24 weeks in combination with placebo tablet daily. The total duration of blinded therapy is 100 weeks (a total of 5 cycles of therapy BCD-132 in combination with a daily placebo)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriflunomide
Description: 14 mg teriflunomide tablet. Per os. Daily in combination with IV placebo. The total duration of blinded therapy is 100 weeks (a total of 5 cycles of placebo IV therapy in combination with daily administration of teriflunomide)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous infusion in combination with placebo tablet daily. The total duration of blinded therapy is 100 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-132, 500 mg
Description: IV infusion every 24 weeks in combination with placebo tablet daily. The total duration of blinded therapy is 100 weeks (a total of 5 cycles of therapy BCD-132 in combination with a daily placebo)
Study: NCT03631134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: Patients will be gave SGLT2 inhibitor 10mg per day
Study: NCT00704288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL184
Description: Gelatin capsules supplied in 25-mg and 100-mg strengths; continuous daily dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL184
Description: Gelatin capsules supplied in 25-mg and 100-mg strengths; continuous daily dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL184
Description: Gelatin capsules supplied in 25-mg and 100-mg strengths; continuous daily dosing
Study: NCT03536559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNM-Au8
Description: CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNM-Au8
Description: CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is liquid with identical color and taste
Study: NCT01055314

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT01951924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)
Study: NCT04361240

Intervention type: RADIATION
Intervention: Proton vs Photon Radiation
Description: Assignment to proton vs photon by randomization on RadComp parent study.
Study: NCT01500291

Intervention type: OTHER
Intervention: 2 courseware databases.
Description: All participant voluntarily response all items in the SST and SAST courseware database.

Intervention type: OTHER
Intervention: 2 courseware databases.
Description: All participant voluntarily response all items in the SST and SAST courseware database.
Study: NCT03585829

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: at a substitutive dosage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: at a substitutive dosage
Study: NCT00727662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iyengar Yoga
Description: The poses and breathing techniques to be used in this study are based on sequences developed by B.K.S. Iyengar for breast cancer survivors who suffer from fatigue. Women will start with simple versions of the poses and progress to more advanced versions over the course of the intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wellness Seminar Series
Description: The Wellness Seminar Series consists of lectures on key topics, followed by group discussion. This series will focus entirely on cancer survivorship, including sessions on quality of life, side effects of cancer treatment, stress, nutrition and psychosocial issues.
Study: NCT01074060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plerixafor
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: autologous hematopoietic stem cell transplantation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02895477

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hearing aid

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hearing aid
Study: NCT02973399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNX-5422 plus ibrutinib
Description: SNX-5422 capsule(s) dosed every other day for 21 days out of a 28-day treatment cycle to a total dose of 56 mg/m2 SNX-5422. Subjects will self-administer daily oral ibrutinib in the afternoon at least 8 hours apart from SNX-5422 for 28 days of each cycle.
Study: NCT01215045

Intervention type: DEVICE
Intervention: AcrySof ReSTOR Aspheric +4
Description: Implantation with the AcrySof ReSTOR Aspheric +4 Multifocal Intraocular Lens (IOL)
Study: NCT03549546

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood samples
Description: Blood samples will be collected in patients undergoing lung cancer surgery:~* before lung cancer surgery,~* the next day lung cancer surgery,~* 3 days after lung cancer surgery. They will be treated in flow cytometry.
Study: NCT01951924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological: Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological: Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL)
Study: NCT04254341

Intervention type: OTHER
Intervention: patients with OSA
Description: Sleep study

Intervention type: OTHER
Intervention: patients with OSA
Description: Sleep study
Study: NCT00606632

Intervention type: DRUG
Group type: OTHER
Intervention: 124-Iodine-cG250 (124I-cG250)
Description: i.v. and PET/CT scan 4+/-2 days after administration

Intervention type: PROCEDURE
Group type: OTHER
Intervention: CT
Description: contrast enhanced CT scan
Study: NCT00784108

Intervention type: DEVICE
Group type: OTHER
Intervention: Modulated Imaging (MI)
Description: Modulated Imaging measure effect of Photodynamic therapy treatment

Intervention type: OTHER
Group type: OTHER
Intervention: Photodynamic therapy
Description: Modulated Imaging measure effect of Photodynamic therapy treatment
Study: NCT01138787

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Reference spread
Description: Single dose (30 gr) of spread, containing 2250 mg PS

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo spread
Description: Single dose (30 gr) of regular light margarine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Test spread
Description: Single dose (30 gr) of innovatively processed spread containing 2250 mg PS.
Study: NCT02083068

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine PvCS N+C+R
Description: Vaccine PvCS N+C+R 60 mcg, freeze dried powder, Batch n°P0RGB, Exp: 18.10.2015 At month 2 and 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine PvCS N+C
Description: Vaccine PvCS N+C 60 mcg, freeze dried powder, Batch n°P0RGA, Exp: 18.10.2015, at month 0

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SSN Montanide ISA-51
Description: SSN Montanide ISA-51 1 mL
Study: NCT06188221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: The group with the lidocaine will get a combined injection with a corticosteroid and lidocaine. The dosages depend on the disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticoids
Description: The group without the lidocaine will get an injection with only corticosteroids. The corticosteroid dosage depends on the disease and will be the same as for the group with the lidocaine:

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticoids
Description: The group without the lidocaine will get an injection with only corticosteroids. The corticosteroid dosage depends on the disease and will be the same as for the group with the lidocaine:
Study: NCT03212235

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation therapy
Description: Hypofractionated radiation therapy Total dose: 60 Gy (20 fractions / 3 Gy per fraction)
Study: NCT01068483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Study: NCT02291991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-E2
Description: Investigational drug(GX-E2 or Placebo) will be administered to healthy volunteers by the intravenous route.
Study: NCT03440398

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic NSM
Description: Surgical technique conducted using robot to perform nipple sparing mastectomy and breast reconstruction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open NSM
Description: Open nipple-sparing mastectomy and immediate breast reconstruction with implant
Study: NCT00758576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACRYSOF Multifocal Single-piece Intraocular Lens (IOL) Model SN6AD1
Description: Implantation with the AcrySof ReSTOR Intraocular Lens (IOL) Model SN6AD1 following cataract removal.
Study: NCT04064463

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: standard treatment for substance use disorders, along with sample monitoring

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard care
Description: standard treatment for substance use disorders, along with sample monitoring

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management
Description: Participants can earn reinforcement for attending group and abstinence from alcohol
Study: NCT02221804

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 14 days of voluntary step count reduction to no more than 1500 steps/day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 14 days of voluntary step count reduction to no more than 1500 steps/day.
Study: NCT04540627

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palivizumab
Description: Liquid solution in sterile water for injection (final concentration of 20mg/mL), intravenous infusion, single dose of 8mg/kg or 15mg/kg, administered at a rate of 1mL/min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride 0.9% Solution (Normal Saline), intravenous infusion, single dose of 0mg/Kg, administered at a rate of 1mL/min

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RSV-A Memphis 37b virus
Description: Single Intranasal Virus Dose (challenge dose is approximately 4.5log10 PFU)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: RSV-A Memphis 37b virus
Description: Single Intranasal Virus Dose (challenge dose is approximately 4.5log10 PFU)
Study: NCT01265719

Intervention type: OTHER
Intervention: No intervention other than routine medical care
Description: Subjects continuously treated with Latanoprost for at least one month Latanoprost treatment during the study period.

Intervention type: OTHER
Intervention: No intervention other than routine medical care
Description: Subjects not treated with any topical prostaglandin analogues or continuously treated with topical prostaglandin analogues for less than one month before the baseline examination, and unlikely to be treated with topical prostaglandin analogues during the study period.
Study: NCT03455556

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anetumab Ravtansine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02530580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg AZD7325
Description: A single 20 mg oral dose of AZD7325

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 20 mg AZD7325
Description: A single 20 mg oral dose of AZD7325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A single oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single oral dose
Study: NCT03596697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRV431
Description: Single or multiple dose(s) of CRV431
Study: NCT03280446

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intragen fractional radiofrequency with NeuViVa
Description: The Transcutaneous Fractional Radiofrequency Device (TFRF) is a minimal risk device that is currently cleared by the FDA K142833.The device uses a non-invasive, transepithelial treatment probe to elevate epithelial tissue temperatures to 40-45 oC for the purpose of promoting tissue contracture. Real-time tissue impedance monitoring will be carried out using the treatment probe.
Study: NCT04918251

Intervention type: PROCEDURE
Intervention: 128 electrode electroencephalography (EEG)
Description: 128 electrode EEG will be non-invasively recorded from electrodes placed in a montage over the scalp while the participant is resting or performing tasks designed to engage specific cortical motor networks of interest (cognitive, behavioural, motor and sensory)

Intervention type: PROCEDURE
Intervention: 128 electrode electroencephalography (EEG)
Description: 128 electrode EEG will be non-invasively recorded from electrodes placed in a montage over the scalp while the participant is resting or performing tasks designed to engage specific cortical motor networks of interest (cognitive, behavioural, motor and sensory)

Intervention type: PROCEDURE
Intervention: 128 electrode electroencephalography (EEG)
Description: 128 electrode EEG will be non-invasively recorded from electrodes placed in a montage over the scalp while the participant is resting or performing tasks designed to engage specific cortical motor networks of interest (cognitive, behavioural, motor and sensory)
Study: NCT02477956

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3 (Replesta)
Description: vitamin D group receive 2 replesta tablets (100,000 IU/month) of cholecalciferol.
Study: NCT04918251

Intervention type: PROCEDURE
Intervention: 128 electrode electroencephalography (EEG)
Description: 128 electrode EEG will be non-invasively recorded from electrodes placed in a montage over the scalp while the participant is resting or performing tasks designed to engage specific cortical motor networks of interest (cognitive, behavioural, motor and sensory)
Study: NCT02477956

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D
Study: NCT00137176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebif
Description: Rebif 44mcg TIW
Study: NCT03171376

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root canal treatment and coronal restoration
Description: After primary root canal treatment, Glass Ionomer Cement (Ketac™ Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.
Study: NCT04918251

Intervention type: PROCEDURE
Intervention: Transcranial magnetic stimulation (TMS)
Description: Single and paired pulse TMS protocol will be delivered while surface bipolar EMG is recorded over hand muscles to interrogate corticospinal tract function and cortical motor network component functions

Intervention type: PROCEDURE
Intervention: Transcranial magnetic stimulation (TMS)
Description: Single and paired pulse TMS protocol will be delivered while surface bipolar EMG is recorded over hand muscles to interrogate corticospinal tract function and cortical motor network component functions

Intervention type: PROCEDURE
Intervention: Transcranial magnetic stimulation (TMS)
Description: Single and paired pulse TMS protocol will be delivered while surface bipolar EMG is recorded over hand muscles to interrogate corticospinal tract function and cortical motor network component functions

Intervention type: PROCEDURE
Intervention: Transcranial magnetic stimulation (TMS)
Description: Single and paired pulse TMS protocol will be delivered while surface bipolar EMG is recorded over hand muscles to interrogate corticospinal tract function and cortical motor network component functions
Study: NCT02572492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction with CAR-CY-DEX and conditioning with carfilzomib and highdose melphalan
Description: All patients entering the study receive four series of CAR-CY-DEX (Cycle 1 with iv carfilzomib 20 mg/sqm on days 1 and 2, and iv carfilzomib 36 mg/sqm on days 8, 9, 15 and 16. Cycle 2 - 4 with iv carfilzomib 36 mg/sqm on days 1, 2, 8, 9, 15 and 16. P.o. cyclophosphamide 300 mg/sqm on days 1, 8 and 15 and p.o. dexamethasone 20 mg on days 1, 2, 8, 9, 15 and 16 in each 28-days series)~Subsequently all patients receive the conditioning regimen:~Iv carfilzomib 27 mg/sqm on day -2 and -1 Iv melphalan 200 mg/sqm on day -2 \> 2.0 m CD34+ stem cells/kg body weight on day 0

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Induction with CAR-CY-DEX and conditioning with carfilzomib and highdose melphalan
Description: All patients entering the study receive four series of CAR-CY-DEX (Cycle 1 with iv carfilzomib 20 mg/sqm on days 1 and 2, and iv carfilzomib 36 mg/sqm on days 8, 9, 15 and 16. Cycle 2 - 4 with iv carfilzomib 36 mg/sqm on days 1, 2, 8, 9, 15 and 16. P.o. cyclophosphamide 300 mg/sqm on days 1, 8 and 15 and p.o. dexamethasone 20 mg on days 1, 2, 8, 9, 15 and 16 in each 28-days series)~Subsequently all patients receive the conditioning regimen:~Iv carfilzomib 27 mg/sqm on day -2 and -1 Iv melphalan 200 mg/sqm on day -2 \> 2.0 m CD34+ stem cells/kg body weight on day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib/dexamethasone maintenance
Description: Maintenance therapy two months after salvage HDT with iv carfilzomib 27 mg/sqm every second week and p.o. dexamethasone 20 mg every second week. The maintenance dose of carfilzomib will be escalated to 56 mg/sqm after 4 weeks provided acceptable side effects.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Observation without carfilzomib/dexamethasone maintenance
Description: Observation without carfilzomib/dexamethasone maintenance
Study: NCT03511222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorolanib
Description: Patients should take vorolanib at approximately the same time every day with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorolanib
Description: Patients should take vorolanib at approximately the same time every day with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorolanib
Description: Patients should take vorolanib at approximately the same time every day with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Standard of care
Study: NCT03726840

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fragrance
Description: peppermint, rosemary, and zest/pulp will increase memory recall for navigation and improve reaction times for braking, compared to performance during unscented conditions
Study: NCT04622059

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: acoustic stimulation
Description: An auditive stimulus was produced by hitting a diapason on an acoustic surface, at a distance of 2-3 cm from the mother's skin (in order to avoid mechanical vibration to reach the fetus) in the area near the fetus' head.~The same procedure was repeated three times, waiting 30 seconds between one stimulus and the following one. The total duration of stimulation was about 2 minutes.
Study: NCT02808299

Intervention type: OTHER
Intervention: HBV infection history
Description: HBV infection history or HBV carriers
Study: NCT03596697

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single Placebo dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF
Description: Single or multiple dose(s) of TDF
Study: NCT01393925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parecoxib
Description: parecoxib 40mg at 30min before the end of surgery, at 8h and 20h after the surgery, intravenously